Johnson & Johnson's sales grew 3.5% during the past year, but only because of big sales growth from a handful of its recently launched drugs. Among these fast-growing new drugs are Johnson's next-generation treatment for diabetes, a new anticoagulant that's displacing warfarin's decades long market share leadership, and a multi-billion dollar drug for tough-to-treat prostate cancer.
However, all three of these drugs are facing challenges that may threaten their market share. Competitors, including AstraZeneca (NYSE:AZN) Pfizer (NYSE:PFE), Medivation (NASDAQ:MDVN), and Astellas (NASDAQOTH:ALPMY)are lining up to try and capture Johnson's market share in these indications.
In the following slideshow, you'll learn what these three drugs are, which companies are challenging their dominance, and seven important questions you should be asking about them this year.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
Todd Campbell is long Medivation. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.